vlx600 and Gastrointestinal-Stromal-Tumors

vlx600 has been researched along with Gastrointestinal-Stromal-Tumors* in 1 studies

Other Studies

1 other study(ies) available for vlx600 and Gastrointestinal-Stromal-Tumors

Article	Year
Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor. Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 02-15, Volume: 24, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hydrazones; Imatinib Mesylate; Metabolic Networks and Pathways; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Mitochondria; Protein Kinase Inhibitors; Treatment Outcome; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays	2018

Article

Year

Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 02-15, Volume: 24, Issue:4

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hydrazones; Imatinib Mesylate; Metabolic Networks and Pathways; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Mitochondria; Protein Kinase Inhibitors; Treatment Outcome; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays

2018